dpa 714
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02405403)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- dpa714
- dpa 714
- dpa-714
- dpa-714
- dpa-714
- n,n-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06289582 | Early Phase 1 (Phase 1) | Aug 14, 2024 | Michael J. Fox Foundation for Parkinson's Research, University of Alabama, Birmingham |
| NCT02405403 | Early Phase 1 (Phase 1) | Mar 1, 2015 | François Rabelais University, University of Toulouse |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| François Rabelais University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Toulouse | Academic/Hospital | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1